Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03936361 | Statins In Intracerbral Hemorrhage | PHASE3 | RECRUITING | 1,456 | — | — | Jun 10, 2020 | Dec 1, 2029 | Apr 21, 2026 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Statin | ACTIVE_COMPARATOR | The same statin agent and dose that subjects were using at the time of ICH onset. |
| No-statin | NO_INTERVENTION | Subjects will discontinue the statin agent that they were taking at the time of ICH onset. No placebo will be prescribed for these subjects. |
| Name | Type | Description |
|---|---|---|
| Statins | DRUG | Statin drugs (already prescribed) at ICH onset will be either continued or discontinued by the participants following qualifying ICH |
Inclusion Criteria: 1. Age ≥ 50 years. 2. Spontaneous lobar ICH confirmed by CT or MRI scan 3. Patient was taking a statin drug at the onset of the qualifying/index ICH 4. Randomization can be carried out within 7 days of the onset of the qualifying ICH 5. Patient or legally authorized representati...